MAPK

Day One Biopharmaceuticals understands that advances in cancer research now allow drug developers to determine children and adults who may benefit from the same medicine.

Day One is a unique biopharmaceutical company on a mission to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Their distinctive approach, together with their trusted network of pediatric oncology investigators, gives them an unmatched ability to advance promising discoveries for patients of all ages. They are prepared to pursue the full potential of their therapies to improve the greatest number of lives as quickly as possible.

What Day One Biopharmaceuticals says about their mission:

"We’re ready to deliver a lasting impact for children with cancer by making sure modern targeted treatments can get to those who need them most. How? Through our deep understanding of biology and the pediatric community. We have a purposeful approach to drug development. And the right mix of people, experience and skills to drive real lasting change. We’re ready to introduce new ground-breaking treatments. Ready to be dedicated, long-term partners. Ready to solve the challenges faced by children with cancer."

Also see: Parexel International